Dr. Reddy's Laboratories is a global pharmaceutical company based in India, primarily engaged in the development, manufacturing, and marketing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. The company operates in various segments, including pharmaceuticals, biotechnology, and consumer healthcare. Major revenue sources include sales of generic drugs in various therapeutic areas, along with contributions from its API and biosimilars divisions.
The investment profile of Dr. Reddy's Laboratories suggests it may be more aligned with value investors, given its current market position and financial metrics. The stock exhibits characteristics that could appeal to those seeking stability rather than aggressive growth. Investors should consider the company's performance trends and market conditions when evaluating its suitability for their portfolios.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-10-23 | Buy | Hold | Mixed performance; analyst signals lack strong confirmation. |
| 2026-10-15 | Hold | Buy | Mixed signals; monitor for improved fundamentals and momentum. |
| 2026-09-29 | Sell | Hold | Weak momentum and EPS surprise raise uncertainty. |
| 2026-07-25 | — | Sell | Weak momentum and fundamentals indicate high risk. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-25 | Jefferies | Rating Upgraded | — → 13.9 | 13.21 |
| 2026-10-12 | BNP Paribas | Rating Upgraded | — → 14.8 | 12.48 |
